Literature DB >> 2894399

Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants.

E L Anderson1, R B Belshe, J Bartram.   

Abstract

Clinical and serological responses of infants to primary immunization with diphtheria-tetanus-pertussis (DTP) vaccine containing components of acellular pertussis vaccine (DTP-AC) were compared in a double-blind study with responses of infants receiving whole-cell DTP vaccine (DTP-WC). Three doses of either DTP-AC containing lymphocytosis-promoting factor (LPF) and filamentous hemagglutinin (FHA) or DTP-WC vaccine were given to infants at two, four, and six months of age. Nineteen infants received DTP-AC vaccine, and 20 infants received DTP-WC vaccine. Significantly more infants who received DTP-WC vaccine manifested fever, swelling, and/or total reactions than did infants who received DTP-AC vaccine. Infants who received DTP-AC vaccine had comparable antibody titers to LPF and significantly higher titers to FHA after three immunizations, as compared with the infants who received DTP-WC vaccine (P less than or equal to .001). The DTP-WC vaccine stimulated higher pertussis agglutination titers (P = .04) than did DTP-AC. The DTP-AC vaccine was immunogenic and significantly less reactogenic in infants than was the currently used DTP-WC vaccine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894399     DOI: 10.1093/infdis/157.4.731

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

2.  Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis.

Authors:  Gráinne H Long; Alexia T Karanikas; Eric T Harvill; Andrew F Read; Peter J Hudson
Journal:  Proc Biol Sci       Date:  2010-03-03       Impact factor: 5.349

Review 3.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

Review 5.  Acellular pertussis vaccines. Towards an improved safety profile.

Authors:  M E Pichichero
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

6.  Photolabelling of mutant forms of the S1 subunit of pertussis toxin with NAD+.

Authors:  W Cieplak; C Locht; V L Mar; W N Burnette; J M Keith
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

7.  Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age.

Authors:  Ronald Gold; Luis Barreto; Santiago Ferro; John Thippawong; Roland Guasparini; William Meekison; Margaret Russell; Elaine Mills; Dana Harrison; Pierre Lavigne
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

Review 8.  Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children.

Authors:  Gladymar Perez Chacon; Jessica Ramsay; Christopher G Brennan-Jones; Marie J Estcourt; Peter Richmond; Patrick Holt; Tom Snelling
Journal:  Cochrane Database Syst Rev       Date:  2021-09-06

9.  Leveraging serology to titrate immunisation programme functionality for diphtheria in Madagascar.

Authors:  Solohery L Razafimahatratra; Arthur Menezes; Amy Wesolowski; Lala Rafetrarivony; Simon Cauchemez; Richter Razafindratsimandresy; Aina Harimanana; Tania Crucitti; Jean Marc Collard; C J E Metcalf
Journal:  Epidemiol Infect       Date:  2022-01-13       Impact factor: 2.451

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.